Eltoprazine HCl (formerly DU-28853; DU28853 hydrochloride) is a novel and potent serenic or antiaggressive agent which also acts as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor. It might be used to treat ADHD, or attention deficit hyperactivity disorder.
Physicochemical Properties
| Molecular Formula | C12H16N2O2 |
| Molecular Weight | 220.26764 |
| Exact Mass | 256.098 |
| Elemental Analysis | C, 56.14; H, 6.67; Cl, 13.81; N, 10.91; O, 12.46 |
| CAS # | 98206-09-8 |
| Related CAS # | Eltoprazine; 98224-03-4; Eltoprazine dihydrochloride; 143485-51-2 |
| PubChem CID | 3025067 |
| Appearance | Solid powder |
| Density | 1.18g/cm3 |
| Boiling Point | 384.3ºC at 760 mmHg |
| Flash Point | 186.2ºC |
| Index of Refraction | 1.562 |
| LogP | 2.063 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 17 |
| Complexity | 231 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [H]Cl.N1(C2=C3OCCOC3=CC=C2)CCNCC1 |
| InChi Key | JFSOSUNPIXJCIX-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C12H16N2O2.ClH/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12;/h1-3,13H,4-9H2;1H |
| Chemical Name | 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine;hydrochloride |
| Synonyms | DU28853; DU 28853; DU-28853; Eltoprazine HCl |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | 5-HT1A Receptor; 5-HT1B Receptor; 5-HT2C Receptor |
| ln Vivo | Long-term treatment with Mianserin (10 mg/kg, i.p.) or Eltoprazine (1 mg/kg, i.p.) and anxiety testing in the elevated plus maze test can be performed. Mianserin and Eltoprazine show opposite effects in the elevated plus maze: Mianserin produces anxiolytic-like effects, while Eltoprazine exhibits anxiolytic-like effects [2]. |
| References |
[1]. Eltoprazine, a drug which reduces aggressive behaviour, binds selectively to 5-HT1 receptor sites in the rat brain: an autoradiographic study. Eur J Pharmacol. 1990 Feb 20;177(1-2):55-66. [2]. Chronic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels. Eur J Pharmacol. 1994 Sep 1;262(1-2):125-31. |
Solubility Data
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (~389.5 mM) DMSO: ≥ 31 mg/mL (~120.8 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (389.51 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5399 mL | 22.6994 mL | 45.3988 mL | |
| 5 mM | 0.9080 mL | 4.5399 mL | 9.0798 mL | |
| 10 mM | 0.4540 mL | 2.2699 mL | 4.5399 mL |